[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369249-105":59,"doc-detail-369249-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pharmacogenomics-based-detection-of-variants-involved-in-pain-anti-inflammatory-and-immunomodulating-agents-pathways-whole-exome-sequencing-and-deep-in-silico-investigations","Pharmacogenomics-Based Detection of Variants Involved in Pain, Anti-inflammatory and Immunomodulating Agents Pathways - Whole Exome Sequencing and Deep in Silico Investigations","","Background: Next-Generation Sequencing (NGS), especially Whole-Exome Sequencing (WES), supports pharmacogenomics (PGx) with high diagnostic accuracy. Cancer pain management represents a modern clinical direction, and a PGx panel can reduce adverse drug reactions while improving efficacy. Methods: WES data from 200 unrelated Iranians were analyzed using a Pain, Anti-inflammatory, and Immunomodulating agents (PAIma) gene panel, followed by ARMS PCR genotyping and in silico interrogation of candidate genes with STRING, miRTargetLink2, and enrichment tools (STRING/Enrichr). Results: 54 variants across 128 genes were prioritized, and actionable candidates were proposed for drug prescribing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pharmacogenomics-based-detection-of-variants-involved-in-pain-anti-inflammatory-and-immunomodulating-agents-pathways-whole-exome-sequencing-and-deep-in-silico-investigations/369249/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pharmacogenomics-based-detection-of-variants-involved-in-pain-anti-inflammatory-and-immunomodulating-agents-pathways-whole-exome-sequencing-and-deep-in-silico-investigations/369249.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What goal did the study pursue in pharmacogenomics testing?","Question",{"text":112,"@type":113},"To examine WES outcomes using a PGx panel targeting genes in pain, anti-inflammatory, and immunomodulating signaling pathways and identify variants relevant to cancer risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were candidate variants and genes selected?",{"text":117,"@type":113},"A PAIma panel was applied to WES results, ARMS PCR genotyped selected samples, and in silico analyses filtered 128 candidate genes using PPI/GMI evidence plus enrichment analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"Which variants were highlighted as potentially actionable for drug prescribing?",{"text":121,"@type":113},"Six variants—rs1695 (GSTP1), rs628031 (SLC22A1), rs17863778 (UGT1A7), rs16947 (CYP2D6), rs2257401 (CYP3A7), and rs2515641 (CYP2E1)—showed major deviations versus the reference genome and were proposed for genotyping before prescribing.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369249,1790387419,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","IJMS  \nVol 50, No 2, February 2025  \nOriginal Article  \nPharmacogenomics-Based Detection of Variants Involved in Pain, Anti-inflammatory and Immunomodulating Agents Pathways by Whole Exome Sequencing and Deep in Silico Investigations Revealed Novel Chemical Carcinogenesis and Cancer Risks  \nAlireza Sharafshah1,2 , PhD candidate; Majid Motovali-Bashi1, PhD; Parvaneh Keshavarz2 , PhD  \n1Division of Genetics, Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran;  \n2Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran  \nCorrespondence:  \nMajid Motovali-Bashi, PhD; University of Isfahan, Azadi Sq. , Postal code: 81746-73441, Isfahan, Iran  \nTel: +98 31 37932474  \n[Email:](Email: mbashi@sci.ui.ac.ir)[ mbashi@sci.ui.ac.ir](Email: mbashi@sci.ui.ac.ir)  \n[Received: 26 February 2024](Received: 26 February 2024)  \n[Revised: 06 April 2024](Revised: 06 April 2024)  \n[Accepted: 25 May 2024](Accepted: 25 May 2024)  \n\n| \u003Cbr>What’s Known\u003Cbr>Next-generation sequencing\u003Cbr>enabled new personalized medicine and pharmacogenomics theranostic options. Whole-exome sequencing panels are wellknown targeted therapy in the diagnosis of disease pathogenicity and risk alleles in many phenotypes including various cancers.\u003Cbr>The pharmacogenomics impacts on carcinogenesis and cancer incidencesin drug consumption, remarkably on pain pathways, are poorly studied.\u003Cbr>\u003Cbr>What’s New |\n| --- |\n| This study investigated the most challenging category of pharmacogenomics known as pain, antiinflammatory, and immunomodulating agent pathways.\u003Cbr>54 variants and 128 genes were suggested, a Pharmacogenomicsbased Multiplex-Amplification Refractory Mutation System by polymerase chain reaction was established, and risks of chemical carcinogenesis resulting from dysregulation of investigated genes were found via in silico analyses. |\n\nAbstract  \nBackground: Next-Generation Sequencing (NGS) methods specifically Whole-Exome Sequencing (WES) have demonstrated promising findings with a high accuracy of 91%-99% in Pharmacogenomics (PGx). A PGx-based panel can be utilized to minimize adverse drug reactions (ADRs) and maximize the treatment efficacy. Remarkably, Cancer Pain Management (CPM) is a cutting-edge concept in modern medicine. Thus, this study aimed to investigate the WES results by a PGx-based panel containing genes involved in Pain, Anti-inflammatory, and Immunomodulating agents (PAIma) signaling pathways. Methods: A total of 200 unrelated Iranians (100 western and 100 northern) were included. 100 WES results were analyzed through the PAIma panel. After DNA extraction, 100 samples were genotyped by Multiplex-Amplification-Refractory Mutation System (ARMS) PCR. A primary insilico investigation performed on 128 candidate genes through Protein-Protein Interactions (PPIs) and Gene-miRNA Interactions (GMIs) via the STRING database, and miRTargetLink2, respectively. Additionally, Enrichment Analysis (EA) was applied to find the unknown interplays among these three major pathways by Enrichr. Results: 55,590 annotations through 21 curated pathways were filtered, 900 variants were found, and 128 genes were refined. Finally, 54 candidate variants (48 non-synonymous single nucleotide variants (nsSNVs), 2 stop-gained, 1 frameshift, and 3 splicing) remained.  \nConclusion: Conclusively, six potentially actionable variants including rs1695 (GSTP1), rs628031 (SLC22A1), rs17863778 ( UGT1A7), rs16947 (CYP2D6), rs2257401 (CYP3A7), andrs2515641 (CYP2E1) had the most deviations among Iranians, compared with the reference genome, which should be genotyped for drug prescribing. Remarkably, PPIs, GMIs, and EA revealed potential risks of carcinogenesis and cancer phenotypes resulting from PAIma pathways genes.  \nPlease cite this article as: Sharafshah AR, Motovali-Bashi M, Keshavarz P. Pharmacogenomics-Based Detection of Variants Involved in Pain,Anti-","cbCailL4rnW1Hodm","https://ap.wps.com/l/cbCailL4rnW1Hodm","pdf",5871117,14,"English","# Background\n# Methods\n## Sample selection and panel analysis\n## ARMS PCR genotyping\n## In silico investigations\n# Results\n# Conclusion","[{\"question\":\"What goal did the study pursue in pharmacogenomics testing?\",\"answer\":\"To examine WES outcomes using a PGx panel targeting genes in pain, anti-inflammatory, and immunomodulating signaling pathways and identify variants relevant to cancer risk.\"},{\"question\":\"How were candidate variants and genes selected?\",\"answer\":\"A PAIma panel was applied to WES results, ARMS PCR genotyped selected samples, and in silico analyses filtered 128 candidate genes using PPI/GMI evidence plus enrichment analysis.\"},{\"question\":\"Which variants were highlighted as potentially actionable for drug prescribing?\",\"answer\":\"Six variants—rs1695 (GSTP1), rs628031 (SLC22A1), rs17863778 (UGT1A7), rs16947 (CYP2D6), rs2257401 (CYP3A7), and rs2515641 (CYP2E1)—showed major deviations versus the reference genome and were proposed for genotyping before prescribing.\"}]","Pharmacogenomics-Based Detection of Variants Involved in Pain, Anti-inflammatory and Immunomodulating Agents Pathways - Whole Exome Sequencing and Deep in Silico Investigations | PDF",1790181610,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87a137657d6898cf74c72695c93a6ae2.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80c77f1bf0bbc620f87419c172fa61cb.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b6b10e56cec640b5cc6e243bc5c6079.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64422380c9f276b4a91fb24e4da4dc9f.webp",980,1385]